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Abstract (195 words) 
Newborn screening for congenital cytomegalovirus (CCMV) using dried blood spots 
(DBS) has been proposed because many developed countries have DBS screening 
programmes in place for other diseases. The aim of this study was to develop a 
rapid, single tube nested polymerase chain reaction (PCR) method for enhanced 
detection of CMV from DBS compared to existing (single target) real time PCRs. The 
new method was compared with existing real time PCRs for sensitivity and 
specificity. Overall sensitivity of the single target PCR assays in both asymptomatic 
and symptomatic infants with laboratory confirmed congenital CMV was 69% (CMV 
PCR or culture positive before day 21 of life). In contrast, the single tube nested 
assay had an increased sensitivity of 81% with100% specificity. Overall the assay 
detected CMV from a DBS equivalent to an original blood sample which contained 
500 IU/ml. In conclusion this single tube nested methodology allows simultaneous 
amplification and detection of CMV DNA in 1.5 hours removing the associated 
contamination risk of a two step nested PCR. Owing to its increased sensitivity, it 
has the potential to be used as a screening assay and ultimately allow early 
identification and intervention for children with congenital CMV. 






Congenital Cytomegalovirus (CCMV) infection occurs in 0.7% of births causing long-
term sensorineural hearing loss (SNHL) and neurological impairment in a significant 
proportion of infected infants (Dollard et al. 2007). Approximately 12.7% of those 
born with symptoms and 13.5% who are asymptomatic at birth, face a significant risk 
of developing late sequelae commonly SNHL (Dollard et al. 2007). Such is the 
burden of disease caused by CMV that the Institute of Medicine ranked the 
development of a CMV vaccine as the highest priority (Stratton et al.,1999). 
Recently, encouraging results have been published from CMV vaccine trials (Griffiths 
et al. 2011;Pass et al. 2009)  but  decades will be required to control CMV infection 
in the community even if a vaccine is used for universal immunisation. (Griffiths 
2012). Therefore there is still an urgent need to identify infected children early for 
interventions to protect speech and language development, such as hearing aids, 
cochlear implants or speech therapy. In addition, a randomised controlled trial of 
ganciclovir, given for six weeks to babies born with CNS symptoms of CCMV, 
reported significant protection against progressive hearing impairment (Kimberlin et 
al. 2003). 
 
The diagnosis of CCMV is challenging. Perinatal CMV infection is acquired  
commonly at birth or through breast feeding. Although this does not cause CNS 
damage, the timing of sampling is pivotal because a diagnosis of CCMV cannot be 
made with certainty in children unless samples are available within 21 days of birth. 
Early accurate diagnosis of CCMV is essential to allow prompt recognition of 
sequelae and provide the opportunity for treatment. Dried blood spots (DBS) are 
taken routinely after birth in many countries for biochemical and genetic analysis and 
are stored for prolonged periods of time. Numerous proof-of-concept studies 
conducted over the last decade have shown that CMV can be detected in DBS. 
(Barbi et al. 2000;Shibata et al. 1994) Owing to the timing of sample acquisition, 
DBS have been shown to be useful in retrospective diagnosis of child presenting 
with compatible symptoms later in infancy or childhood (Barbi et al. 2006;Vauloup-
Fellous et al. 2007;Walter et al. 2008). These studies have used a variety of patient 
populations and methods for both extraction of nucleic acid and CMV detection from 
the DBS matrix, resulting in a wide range of reported sensitivities (28-100%) mainly 
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attributable to methodology (Boppana et al. 2010;de Vries et al. 2009;Vauloup-
Fellous et al 2007)  The sensitivity reported by the largest reported study was about 
30% (Boppana, et al 2010).  
Currently, no country screens for CCMV; the use of DBS for newborn screening has 
been proposed.  DBS samples are by definition small-volume collections often with 
only 10-80µl of whole blood available for analysis, so highly sensitive detection 
methods such as nested PCR are needed. Published methods with high sensitivity 
use manual DNA extraction methods and nested PCR with gel based detection 
which are not suitable for high throughput due to the inherent potential for cross 
contamination and the labour intensive nucleic acid extraction step. 
 
 
 This study describes the development and validation of a novel single tube nested 
PCR for enhanced detection of CMV from DBS which has the potential for use as a 
high throughput screening assay to facilitate the prompt identification and 
intervention in children with CCMV. 
 
 2 Material and methods 
2.1 Samples 
 DBS samples were tested from 4 sample sets. 
1. Artificial CMV negative and positive DBS prepared from the World Health 
Organisation 1st International standard for CMV (who/35/10.2138 report). 
Serial dilutions from 500,000IU/ml - 100 IU/ml were prepared in a whole blood 
matrix and 50µl absorbed onto standard Whatman 903™ DBS cards obtained 
from the Royal Free Hospital neonatal unit. The prepared cards were dried for 
a minimum of 48 hours prior to testing.  
 
2. 20 DBS samples from newborns with CCMV infection were obtained from an 
earlier published study.  The cases were Children with diagnosed or 
suspected congenital CMV born in the UK between 2001-2002 were reported 
by paediatricians via the BPSU notification system (BPSU 17th Annual report, 
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2002-2003). Cases were confirmed on the basis of PCR or virus isolation from 
urine, blood, saliva or tissue taken at biopsy within 3 weeks of birth. The cards 
had been stored in standard UK storage conditions and all were collected 
within 21 days of life. 
 
3. The 2011 CMV DBS panel (ref CMV/DBS11) obtained from Quality Control for 
Molecular Diagnostics (QCMD, Glasgow UK) The panel comprised 10 DBS.  
Each spot was prepared from a whole blood matrix with varying 
concentrations of CMV (AD169 strain). The stated CMV concentration ranged 
from 625-20,000 copies/ml. One DBS was equivalent to 50µl of whole blood. 
 
4. DBS samples received as part of an ethically approved study (Benefits of 
Extended Screening Testing (BEST Study) from 6 children who failed their 
newborn hearing screen and had CCMV (cases were confirmed on the basis 
of PCR or from urine or saliva); samples were taken within 3 weeks of birth 
(manuscript in preparation).  
 
 
The specificity of the assay was determined by analysing 200 blood samples from 
donor/recipient CMV negative solid organ transplant patients. These samples were 
received for routine post transplant CMV screening and were CMV negative in our 
diagnostic RT PCR assay (Atabani et al. 2012). 
 
2.2 DNA extraction from DBS 
 
A 6.5mm diameter (33mm²) circle of DBS was used for extraction. This size was 
chosen because this is a realistic amount of sample that remains after newborn 
screening. 
To prevent contamination the scissors used to cut the DBS were cleaned with 0.1M 
hydrochloric acid between cards.  
DNA was extracted from DBS using the QIAsymphony automated extraction system 
with the QIAsymphony DNA Mini Kit (Qiagen, Hilden, Germany) following manual 
pre-treatment: DBS was added to 400 μl Buffer ATL and 20 μl proteinase K, and 
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incubated at 56°C for 30 minutes. The resulting supernatant was transferred into a 2 
ml tube, without disturbing the digested DBS, and loaded onto the QIAsymphony SP. 
Extraction was carried out using the VirusBlood200_V5_DSP protocol with an elution 
volume of 60 μl. Each DBS extract was analysed in triplicate. 
 
 
2.3 DNA extraction from whole blood 
DNA was extracted using the QIAsymphony automated extraction system with the 
QIAsymphony DNA Mini Kit (Qiagen, Hilden, Germany).  Extraction was carried out 
using the VirusBlood200_V5_DSP protocol with an elution volume of 60 μl. Each 
blood sample was analysed in triplicate. 
 
2.4 Single tube nested PCR strategy 
A single tube nested PCR that amplified a target in exon 4 of the major immediate 
early region of CMV (UL123) was developed 
Two sets of primers were modified from a previously published method (Taylor-
Wiedeman et al. 1991). External primers (outer 1, 2) were extended to give an 
annealing temperature at least 10°C higher than the internal primers (inner 1,2).   
First round PCR amplification was performed at 68°C, which allowed only the 
external primers to bind and amplify target sequence. The extension temperature 
was reduced to 55°C  so that the target amplified with both the external and internal 
primers. A FAM/ZEN double quenched probe was degraded during the extension 
and the resulting fluorescent monitored in real time. Double quenching was used to 
reduce background and improve reporter signal. Primers and probe were purchased 
from Integrated DNA Technologies (Leuven, Belgium).  A schematic diagram of the 
nested PCR (figure 1) and the primer and probe sequences for the single tube 
nested PCR are summarised in Table 1. 
DNA amplification was performed in 30µl total reaction volume. Each reaction 
contained 10µl of DNA extract 15µl QuantiFAST mastermix (Qiagen, Hilden 
Germany), 1µM of each primer and 0.2µM of probe. Real time PCR was carried out 
in a TaqMan 7500 system (Applied Biosystems, Foster City, CA, USA).  
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PCR conditions were: template denaturation and activation of Taq polymerase for 10 
minutes at 95°C was first followed by 15 cycles of 95°C for 15 seconds and 68°C for 
45 seconds. This was followed by a second cycling step of 95°C and 55°C for 30 
cycles. Data acquisition occurred during the second cycling step (55°C extension). 
 
2.6  CMV gB and UL69 PCR  
The single round real time CMV gB and UL69 PCRs were used as previously 




3.1 Detection limit of single tube nested PCR  
The sensitivity of the single tube nested PCR assay was determined using triplicate 
testing of DBS spotted with serial dilutions of the WHO CMV international standard. 
The lowest positive dilution (1/3 triplicate positive) correlated with an original blood 
sample which contained 500 IU/ml CMV. 
The QCMD samples showed a similar detection limit.  The lowest CMV 
concentration DBS sample (stated as 625 copies/ml) giving was positive in the 




3.2 Specificity of single tube nested PCR 
None of the 200 CMV negative blood samples showed amplification when tested in 
triplicate in the single tube nested PCR assay.  
3.3 Performance and evaluation of single tube Nested PCR with DBS sample 
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Results obtained with the single tube nested PCR assay were compared with those 
generated using the CMV gB assay. All samples were tested in parallel using the 
equivalent input.  
In the QCMD panel all 9 CMV positive samples were identified correctly (100%) in 
the single tube nested PCR assay. In comparison only 6/9 (67%) positive samples 
were identified with the CMV gB assay. The one true CMV negative DBS showed no 
amplification in both assays. The DBS with discordant results corresponded to the 3 
samples with the lowest viral loads 625, 1250 and 2500 copies/ml (viral loads stated 
in the QCMD final report). To confirm that enhanced detection was not due to target 
region or primer design, the QCMD panel was also tested using a real time PCR 
CMV UL69 assay. The same 6/9 samples tested positive in the assay for the UL69 
region as the gB assay. 
DBS samples obtained from 20 children with laboratory confirmed CCMV gave 
positive results in 18/20 (90%) samples with the single tube nested assay. 16/20 
samples tested positive in the CMV gB real time assay (80%), again showing 
enhanced detection with the single tube nested PCR (figure 2). The two negative 
samples in the single tube assay were also negative in the gB assay. In the DBS 
received from infants identified through the BEST study (failed NHSP) 3/6 cards 
tested positive by the single tube assay (50%) compared with 2/6 with the single 
round PCR (33%). Reviewing laboratory results in the three negative DBS from 
children identified through the BEST study, two children had blood samples taken for 
CMV PCR in the neonatal period both of which were undetectable (<200 copies/ml).    
 Overall sensitivity of the single tube nested PCR assay in identifying neonates with 
confirmed CCMV was 21/26 (81%; 95% CI, 60.6%-93.4%). In contrast the single 
step gB real time PCR had a sensitivity of 18/26 (69%;95% CI, 48.2%-85.6%) giving 
an increased detection rate of 12% in children with laboratory diagnosed CCMV 
infection. 
After analysis of the clinical data from the 20 confirmed CCMV children the two 
negative samples had asymptomatic presentation with a normal clinical outcome (no 
problems reported, apparently normal development) at follow up (20.8 and 20.5 
months after birth; (table 2). On further investigation, the additional positive DBS in 
the CCMV failed NHSP samples had a sample of whole blood tested in the neonatal 
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period (prior to the DBS being taken) with a viral load of 7,700 copies/ml. The child 
presented with unilateral SNHL and subependymal cysts on cranial imaging and 
received 6 weeks’ treatment with valganciclovir. 
Overall the outcome was known in 25/26 CCMV children. The mean follow up period 
was 19.9 months (SD 4.6 months). The single tube nested PCR detected CMV DNA 
in 20/25 samples compared to the gB assay with 17/25 testing positive. On further 
investigation of the 3 samples positive which tested only with the nested PCR, only 
one DBS was from a symptomatic infant with mild SNHL at follow up. The two other 
DBS samples were from symptomatic children with bi –lateral hearing loss at follow-
up (table 2). 
 
 4 Discussion 
This study demonstrates enhanced detection of CMV DNA from DBS using a novel 
single tube nested protocol when compared with a single round PCR.  PCR based 
testing for viral targets often report high sensitivities but use a much larger sample 
volume. For example whilst an HIV RNA viral load assay may detect a sensitivity of 
50 copies/ml an original volume of sample of 1ml would be required. The hypothesis 
was that that the low sensitivity reported from DBS is due to small sample volume 
(typically between 10 and 80ul) and that a detection method with high sensitivity 
would be required in order to detect these very small quantities of CMV. 
Proof of concept studies already exist reporting detection of CMV from DBS. 
However the methods reporting the highest sensitivities for CMV DNA detection from 
DBS are not suitable for high throughput screening because of labour intensive 
methodologies and/or detection. This study is the first to report a sensitive method 
which has the potential to be used as a high throughput screening tool.  
Newborn screening for CMV has been suggested using saliva or urine samples due 
to their reported high sensitivities (Boppana et al. 2011). However DBS have the 
advantage that newborn screening programmes using DBS (Guthrie cards) are 
already in place in many countries. Thus DBS samples are available on every child 
born without any additional sample requirements.  
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Recently a study by Boppana et al reported DBS to have low sensitivity when 
compared to saliva rapid culture. (Boppana et al, 2010) It has been shown that DNA 
extraction and CMV detection methods can have significant effect on the reported 
assay sensitivity. (de Vries, et al 2009);(Soetens et al. 2008) highlighting the 
importance of assay methodology. This study shows that existing DBS methodology 
can be improved; however a study to address the methods clinical sensitivity 
compared to urine or saliva in the context of CCMV newborn screening is warranted. 
In the current study, the overall sensitivity was 81%. Interestingly the 5 CMV 
negative samples from confirmed CCMV cases were asymptomatic infants with 
normal outcome at follow up. Studies using PCR quantitation have shown that viral 
load in urine and blood at birth is higher in symptomatic babies compared to 
asymptomatic babies, but more importantly that level of viraemia correlates with  
future sensorineural hearing loss (Boppana et al. 2005;Bradford et al. 2005).  In solid 
organ transplant patients quantitative studies have likewise shown that risk of 
disease is associated with high viral load (Cope et al. 1997). A sigmoid relationship 
has been proposed recently for the severity of SNHL versus CMV viral load at birth 
(Walter et al, 2008). However this ‘threshold effect’ is novel in the context of newborn 
screening and denotes that a test without 100% analytical sensitivity that 
nevertheless detected all children at risk of developing disease would be deemed 
acceptable for the purposes of screening. Our data seem to support this as the DBS 
from the asymptomatic children with normal outcome are CMV PCR negative in 
contrast to the symptomatic children with severe outcome who had CMV detected in 
all DBS screened. This possibility should now be evaluated in much larger numbers 
of cases and controls to determine whether an assay with less than 100% sensitivity 
for infection could nevertheless identify all cases destined to develop disease.  
Traditionally newborn screening for genetic and biochemical disorders was based on 
mass spectrometry. The first DNA based newborn screen for severe combined 
immunodeficiency (SCID) was included in the US screening core panel in 2010. The 
assay is based on the detection and quantitation of T cell receptor excision circles 
(TREC) from DBS by real time PCR (Kwan et al. 2013). Currently the UK is running 
a pilot study for SCID screening and, if implemented, the TREC assay will be the first 
DNA based screen to be added to the UK screening panel. This will provide the 
10 
 
expertise and instrumentation required for DNA extraction and real time PCR. Once 
these are in place it will provide the ideal opportunity for the addition of new 
molecular based tests into the newborn screening repertoire including those for 
CMV. 
This data show that detection of CMV from DBS is possible and that inclusion of 
CMV screening in the newborn programme is feasible. Overall this will allow a 
greater number of infected infants to be identified early and provide the opportunity 
for intervention.  
 
 5 Conclusions 
A novel real time single tube nested PCR was developed for improved detection of 
CCMV from DBS. This rapid single tube nested PCR allows detection of CMV in 
1.5hrs and removes the associated contamination risk of a two step nested PCR 




The authors would like to thank the staff at the Department of Virology, Royal Free 







Atabani, S.F., Smith, C., Atkinson, C., Aldridge, R.W., Rodriguez-Peralvarez, M., Rolando, N., Harber, 
M., Jones, G., O'Riordan, A., Burroughs, A.K., Thorburn, D., O'Beirne, J., Milne, R.S., Emery, V.C., & 
Griffiths, P.D. 2012. Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients 
Managed by Preemptive Therapy. Am.J.Transplant. available from: PM:22594993  
Atkinson, C., Walter, S., Sharland, M., Tookey, P., Luck, S., Peckham, C., & Griffiths, P. 2009. Use of 
stored dried blood spots for retrospective diagnosis of congenital CMV. J.Med.Virol., 81, (8) 1394-
1398 available from: PM:19551829  
Barbi, M., Binda, S., & Caroppo, S. 2006. Diagnosis of congenital CMV infection via dried blood spots. 
Rev.Med.Virol., 16, (6) 385-392 available from: PM:17004294  
Barbi, M., Binda, S., Primache, V., Caroppo, S., Dido, P., Guidotti, P., Corbetta, C., & Melotti, D. 2000. 
Cytomegalovirus DNA detection in Guthrie cards: a powerful tool for diagnosing congenital infection. 
J.Clin.Virol., 17, (3) 159-165 available from: PM:10996112  
Boppana, S.B., Fowler, K.B., Pass, R.F., Rivera, L.B., Bradford, R.D., Lakeman, F.D., & Britt, W.J. 2005. 
Congenital cytomegalovirus infection: association between virus burden in infancy and hearing loss. 
J.Pediatr., 146, (6) 817-823 available from: PM:15973325  
Boppana, S.B., Ross, S.A., Novak, Z., Shimamura, M., Tolan, R.W., Jr., Palmer, A.L., Ahmed, A., 
Michaels, M.G., Sanchez, P.J., Bernstein, D.I., Britt, W.J., & Fowler, K.B. 2010. Dried blood spot real-
time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. 
JAMA, 303, (14) 1375-1382 available from: PM:20388893  
Boppana, S.B., Ross, S.A., Shimamura, M., Palmer, A.L., Ahmed, A., Michaels, M.G., Sanchez, P.J., 
Bernstein, D.I., Tolan, R.W., Jr., Novak, Z., Chowdhury, N., Britt, W.J., & Fowler, K.B. 2011. Saliva 
polymerase-chain-reaction assay for cytomegalovirus screening in newborns. The New England 
Journal of Medicine, 364, (22) 2111-2118 available from: PM:21631323  
Bradford, R.D., Cloud, G., Lakeman, A.D., Boppana, S., Kimberlin, D.W., Jacobs, R., Demmler, G., 
Sanchez, P., Britt, W., Soong, S.J., & Whitley, R.J. 2005. Detection of cytomegalovirus (CMV) DNA by 
polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital 
CMV infection involving the central nervous system. J.Infect.Dis., 191, (2) 227-233 available from: 
PM:15609232  
Cope, A.V., Sweny, P., Sabin, C., Rees, L., Griffiths, P.D., & Emery, V.C. 1997. Quantity of 
cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. 
J.Med.Virol., 52, (2) 200-205 available from: PM:9179769  
de Vries, J.J., Claas, E.C., Kroes, A.C., & Vossen, A.C. 2009. Evaluation of DNA extraction methods for 
dried blood spots in the diagnosis of congenital cytomegalovirus infection. J.Clin.Virol., 46 Suppl 4, 
S37-S42 available from: PM:19781984  
Dollard, S.C., Grosse, S.D., & Ross, D.S. 2007. New estimates of the prevalence of neurological and 
sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev.Med 
Virol., 17, (5) 355-363 available from: PM:17542052  
12 
 
Griffiths, P.D. 2012. Burden of disease associated with human cytomegalovirus and prospects for 
elimination by universal immunisation. Lancet Infect.Dis., 12, (10) 790-798 available from: 
PM:23017365  
Griffiths, P.D., Stanton, A., McCarrell, E., Smith, C., Osman, M., Harber, M., Davenport, A., Jones, G., 
Wheeler, D.C., O'Beirne, J., Thorburn, D., Patch, D., Atkinson, C.E., Pichon, S., Sweny, P., Lanzman, 
M., Woodford, E., Rothwell, E., Old, N., Kinyanjui, R., Haque, T., Atabani, S., Luck, S., Prideaux, S., 
Milne, R.S., Emery, V.C., & Burroughs, A.K. 2011. Cytomegalovirus glycoprotein-B vaccine with MF59 
adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet, 377, (9773) 
1256-1263 available from: PM:21481708  
Kimberlin, D.W., Lin, C.Y., Sanchez, P.J., Demmler, G.J., Dankner, W., Shelton, M., Jacobs, R.F., 
Vaudry, W., Pass, R.F., Kiell, J.M., Soong, S.J., & Whitley, R.J. 2003. Effect of ganciclovir therapy on 
hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a 
randomized, controlled trial. J.Pediatr., 143, (1) 16-25 available from: PM:12915819  
Kwan, A., Church, J.A., Cowan, M.J., Agarwal, R., Kapoor, N., Kohn, D.B., Lewis, D.B., McGhee, S.A., 
Moore, T.B., Stiehm, E.R., Porteus, M., Aznar, C.P., Currier, R., Lorey, F., & Puck, J.M. 2013. Newborn 
screening for severe combined immunodeficiency and T-cell lymphopenia in California: Results of 
the first 2 years. J.Allergy Clin.Immunol., 132, (1) 140-150 available from: PM:23810098  
Pass, R.F., Zhang, C., Evans, A., Simpson, T., Andrews, W., Huang, M.L., Corey, L., Hill, J., Davis, E., 
Flanigan, C., & Cloud, G. 2009. Vaccine prevention of maternal cytomegalovirus infection. N Engl J 
Med, 360, (12) 1191-1199 available from: PM:19297572  
Shibata, M., Takano, H., Hironaka, T., & Hirai, K. 1994. Detection of human cytomegalovirus DNA in 
dried newborn blood filter paper. J.Virol.Methods, 46, (2) 279-285 available from: PM:8188821  
Soetens, O., Vauloup-Fellous, C., Foulon, I., Dubreuil, P., De, S.B., Grangeot-Keros, L., & Naessens, A. 
2008. Evaluation of different cytomegalovirus (CMV) DNA PCR protocols for analysis of dried blood 
spots from consecutive cases of neonates with congenital CMV infections. J.Clin.Microbiol., 46, (3) 
943-946 available from: PM:18199787  
Taylor-Wiedeman, J., Sissons, J.G., Borysiewicz, L.K., & Sinclair, J.H. 1991. Monocytes are a major site 
of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J.Gen.Virol., 72 ( Pt 
9), 2059-2064 available from: PM:1654370  
Vauloup-Fellous, C., Ducroux, A., Couloigner, V., Marlin, S., Picone, O., Galimand, J., Loundon, N., 
Denoyelle, F., Grangeot-Keros, L., & Leruez-Ville, M. 2007. Evaluation of cytomegalovirus (CMV) DNA 
quantification in dried blood spots: retrospective study of CMV congenital infection. J.Clin.Microbiol., 
45, (11) 3804-3806 available from: PM:17898161  
Walter, S., Atkinson, C., Sharland, M., Rice, P., Raglan, E., Emery, V.C., & Griffiths, P.D. 2008. 
Congenital cytomegalovirus: Association between dried blood spot viral load and hearing loss. Arch 










Figure 1: Schematic diagram of single tube nested PCR (not to scale) 
A single tube nested PCR was developed to amplify a target in exon 4 of the major immediate early 
region of CMV (UL123). The thermodynamic profile was adapted so that initial 15 cycles of PCR yield 
a 373bp product from the outer primers (Outer1,2). A  second PCR cycle incorporated the inner 
primers (inner 1,2) to yield a 291bp product. A internal double quenched probe allowed simultaneous 




















Table 1 Primers and probes used for single tube nested PCR 




 (Sequence 5’-3’)  Tm Nucleotide 
positiona 
Outer 1  GGTCACTAGTGACGCTTGTATGATGACCATGTACGG  74 172906-172941 
Outer 2  GATAGTCGCGGGTACAGGGGACTCTG  71 172568-172594 
Inner 1  AGTGAGTTCTGTCGGGTGCT  58 172870-172889 










 FAM, 6-carboxyfluorescein; ZEN, internal quencher; IB®FQ Iowa Black dark quencher  








































Table 2- Correlation between neonatal presentation of CCMV, clinical outcome 




Outcome* Number of DBS 
testing positive with 
Single round PCR 
Number of DBS testing 
positive with nested 
single tube PCR 
Asymptomatic Normal 3/7 3/7 
Symptomatic Normal 2/2 2/2 
Symptomatic Mild 5/6 6/6 
Symptomatic Moderate 5/7 7/7 
Symptomatic Severe 3/3 3/3 
 
*Outcome: Normal- No reported problems  Mild: Unilateral hearing loss, mild cerebral 
palsy, mild language delay, Moderate: Bi-lateral profound deafness, deafness and other 
problem   Severe: Multiple serious problems e.g. Severe global delay
